Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionBoth sides next revision |
pharmaceutical_companies:telis_bioscience [2023/03/27 06:08]
liam | pharmaceutical_companies:telis_bioscience [2024/11/18 19:50] (current)
liam [External links] |
|---|
| Telis was founded in 2019 by [[:Grigory Khimulya]] and [[:Kyle Fish]].((//Telis Bioscience - Crunchbase Company Profile & Funding.// Crunchbase. Retrieved March 27, 2023, from https://www.crunchbase.com/organization/telis-bioscience)) ((Grigory Khimulya [@grigonomics]. (2020, September 23). //“Life update: for the past year @fish_kyle3 and I have been building Telis Bioscience, a venture-backed biotech company in Cambridge, MA engineering high-impact protein therapeutics . We’re hiring! (1/5)”// [Tweet]. Twitter. http://archive.today/2023.03.27-011210/https://twitter.com/grigonomics/status/1308768978756567042)) | Telis was founded in 2019 by [[:Grigory Khimulya]] and [[:Kyle Fish]].((//Telis Bioscience - Crunchbase Company Profile & Funding.// Crunchbase. Retrieved March 27, 2023, from https://www.crunchbase.com/organization/telis-bioscience)) ((Grigory Khimulya [@grigonomics]. (2020, September 23). //“Life update: for the past year @fish_kyle3 and I have been building Telis Bioscience, a venture-backed biotech company in Cambridge, MA engineering high-impact protein therapeutics . We’re hiring! (1/5)”// [Tweet]. Twitter. http://archive.today/2023.03.27-011210/https://twitter.com/grigonomics/status/1308768978756567042)) |
| |
| In December 2021, Telis pivoted to focus on developing a [[COVID-19 vaccines|COVID-19 vaccine]] under a new name, [[Alvea]], which launched in January 2022.((McGrath, K. (2022, February 16). //Alvea Launches Scalable, Shelf- Stable DNA Vaccine Development against New SARS-CoV-2 Variants.// PR Newswire. https://web.archive.org/web/20220513024500/https://www.prnewswire.com/news-releases/alvea-launches-scalable-shelf--stable-dna-vaccine-development-against-new-sars-cov-2-variants-301483557.html)) | In December 2021, Telis pivoted to focus on developing a [[:COVID-19 vaccines|COVID-19 vaccine]] under a new name, [[Alvea]], which launched in January 2022.((McGrath, K. (2022, February 16). //Alvea Launches Scalable, Shelf- Stable DNA Vaccine Development against New SARS-CoV-2 Variants.// PR Newswire. https://web.archive.org/web/20220513024500/https://www.prnewswire.com/news-releases/alvea-launches-scalable-shelf--stable-dna-vaccine-development-against-new-sars-cov-2-variants-301483557.html)) |
| |
| ===== Organization ===== | ===== Organization ===== |
| |
| * [[https://www.linkedin.com/company/telisbio/|LinkedIn]] | * [[https://www.linkedin.com/company/telisbio/|LinkedIn]] |
| | * [[https://wiki.whiteroseintelligence.com/en/Telis-Bioscience|White Rose Wiki]] |
